BGNE - ベイジ―ン （BeiGene Ltd.）

The European drug regulator''s human medicines committee has recommended extending the indication for BeiGene''s (BGNE) cancer drug Brukinsa

BeiGene Limited (NASDAQ: BGNE ) shared updates from its solid tumor development program for tislelizumab at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris. The Phase 3 RATIONALE 301 trial of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma met its primary endpoint of overall survival (OS) non-inferiority. The median OS was 15.9 … Full story available on Benzinga.com

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, shared updates from its solid tumor development program for cornerstone PD-1 antibody tislelizumab at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris. Results from the Phase 3 RATIONALE 301

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Company will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th, 2022 with a fireside chat at 9:10 a.m. ET. A live webcast

Amgen Inc. found using ticker (AMGN) now have 22 analysts covering the stock. The analyst consensus points to a rating of ''Hold''. The target price ranges between 295 and 182 with a mean TP of 253.12. Given that the stocks previous close was at 242.37 this now indicates there is a potential upside of 4.4%. The 50 day moving average now sits at 246.52 and the 200 day moving average is 235.9. The market cap for the company is $129,571m. You can visit the company''s website by visiting: https://www.amgen.com [stock_market_widget type="chart" template="basic" color="green" assets="AMGN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $135,318m based on the market concensus. Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company''s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet''s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Chinese biotechnology company, BeiGene (BGNE) announced on Wednesday an agreement to develop messenger RNA-based therapies in partnership with InnoRNA, a biotech with expertise in…

BeiGene announced it entered into a worldwide strategic collaboration with InnoRNA to develop mRNA-based therapeutics.

Novartis (NVS) and BeiGene (BGNE) said tislelizumab plus chemotherapy helped improve overall ((OS)) survival in certain patients with esophageal cancer in a late-stage study.Data from…

Basel, June 30, 2022 — Today Novartis announced results from the Phase III RATIONALE 306 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) as a first-line treatment for adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 status. Tislelizumab plus chemotherapy demonstrated a median OS of 17.2 months (CI, 15.8-20.1 months) versus 10.6 months (CI, 9.3-12.1 months) in patients receiving chemotherapy plus placebo and reduced the risk of death by 34% (hazard ratio=0.66; CI, 0.54-0.80, p<0.0001). 1 In collaboration with BeiGene, these data were presented today during a late-breaking oral session at the 2022 European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer (Abstract #LBA-1).

- Selinexor is an oral small molecule XPO1 inhibitor ; tislelizumab is an anti-PD-1 checkpoint inhibitor SHANGHAI and HONG KONG , June 27, 2022 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene''s anti-PD-1 checkpoint inhibitor, tislelizumab. This multi-center, open-label Phase I/II trial will evaluate the investigational combination as a potential treatment option for patients with T and NK-cell lymphoma . "We are delighted to partner with BeiGene, a company that strives for innovation and excellence, and is committed to developing best-in-class or first-in-class anti-cancer therapies for patients across the globe.

BeiGene press release (BGNE): Q1 GAAP EPADS of -$4.24 beats by $1.08.Revenue of $306.63M (-49.4% Y/Y) beats by $6.22M.

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported financial results for the first quarter of 2022, recent business highlights, and anticipated upcoming milestones. “I have never been more confident in BeiGene. We made terrific progress in the first quarter with our global commercial performance in the U.S.

China''s National Medical Products Administration ((NMPA)) granted conditional approval to BeiGene (BGNE) and Amgen''s (AMGN) Blincyto injection to treat children with relapsed or…

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administration (NMPA) has granted conditional approval of BLINCYTO (blinatumomab) for injection for the treatment of pediatric

Beijing-based BeiGene (BGNE) announced the groundbreaking of its flagship U.S